Aspira Pathlab

Who are in the management team of Aspira Pathlab?

As of March 2021, the management team of Aspira Pathlab includes Pankaj Jashwant Shah (Managing Director & CEO), Haseeb Drabu (Chairman), and several directors, including independent and executive members. Key roles are filled by Arvind Karsandas Bhanushali, Mangala Radha Krishnan Prabhu, Nikunj Mange, Subhash Raghunath Salunke, A C Mahajan, and Priya Pandey (Company Secretary).

As of March 2021, the management team of Aspira Pathlab includes:<BR><BR>1. Pankaj Jashwant Shah - Managing Director & CEO<BR>2. Arvind Karsandas Bhanushali - Executive Director<BR>3. Arvind Karsandas Bhanushali - Non Executive Director<BR>4. Mangala Radha Krishnan Prabhu - Independent Director<BR>5. Haseeb Drabu - Chairman<BR>6. Nikunj Mange - Director<BR>7. Subhash Raghunath Salunke - Independent Director<BR>8. A C Mahajan - Independent Director<BR>9. Priya Pandey - Company Secretary<BR><BR>Each member plays a significant role in the governance and management of the company.

Has Aspira Pathlab declared dividend?

No Dividend History Available

Who are the peers of the Aspira Pathlab?

Aspira Pathlab's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Aspira Pathlab leads in 1-year returns at 80.64%, while Syngene Intl. has the lowest return at -3.47%.

Peers: The peers of Aspira Pathlab are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., N G Industries, Deccan Healthcar, Centenial Surgic, Bandaram Pharma, and Tejnaksh Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average management risk. Growth is Excellent at Bandaram Pharma, Average at Poly Medicure, Indegene, and the rest, while Below Average growth is seen at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Aspira Pathlab, N G Industries, Deccan Healthcar, Centenial Surgic, and Tejnaksh Health. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Vijaya Diagnost., while Good capital structure is noted at N G Industries, Deccan Healthcar, Centenial Surgic, and the rest have Average or Below Average.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 80.64%, while the lowest is Syngene Intl. at -3.47%. Aspira Pathlab's 1-year return is significantly higher than all its peers. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Deccan Healthcar, and Tejnaksh Health.

Is Aspira Pathlab overvalued or undervalued?

As of May 19, 2025, Aspira Pathlab is considered very attractive due to its strong performance metrics, including a PE ratio of 27.85 and a PEG ratio of 0.16, indicating it is undervalued compared to peers like Dr. Lal PathLabs and Metropolis Healthcare, despite recent underperformance against the Sensex, with a notable 107.67% return over the past year.

As of 19 May 2025, the valuation grade for Aspira Pathlab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently undervalued based on its strong performance metrics. Key ratios include a PE ratio of 27.85, an EV to EBITDA of 16.26, and a PEG ratio of 0.16, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Aspira Pathlab's valuation stands out, particularly against companies like Dr. Lal PathLabs, which has a PE ratio of approximately 40, and Metropolis Healthcare, with an EV to EBITDA of around 25. The robust ROCE of 18.34% and ROE of 18.63% further reinforce the company's strong operational efficiency. While the stock has underperformed the Sensex in shorter time frames, its impressive 107.67% return over the past year highlights its potential for growth, supporting the conclusion that Aspira Pathlab is currently undervalued.

What is the technical trend for Aspira Pathlab?

As of April 2, 2025, Aspira Pathlab's trend is mildly bullish, with mixed signals from key indicators like MACD and Bollinger Bands across different time frames.

As of 2 April 2025, the technical trend for Aspira Pathlab has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating some weakness in momentum. The daily moving averages are mildly bullish, suggesting short-term support. The Bollinger Bands show a mildly bearish stance on the weekly chart but bullish on the monthly, indicating mixed signals across time frames. The KST is bearish weekly but bullish monthly, adding to the complexity of the trend. Overall, the current stance is mildly bullish, with key indicators highlighting mixed momentum and trend signals across different time frames.

What does Aspira Pathlab do?

Aspira Pathlab & Diagnostics Ltd is a micro-cap pathology specialist established in 1973, reporting net sales of 58 Cr and a net profit of 7 Cr for the quarter ending March 2025. The company has a market cap of INR 54 Cr and key metrics include a P/E of 26.00 and a return on equity of 18.63%.

Overview: <BR>Aspira Pathlab & Diagnostics Ltd is a leading pathology specialist in the healthcare services industry, operating within the micro-cap market.<BR><BR>History: <BR>Incorporated in July 1973, Aspira Pathlab & Diagnostics Ltd has established itself as a prominent player in the pathology sector. The latest financial results reported are for the quarter ending March 2025, showcasing the company's ongoing operations.<BR><BR>Financial Snapshot: <BR>Net Sales: 58 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 18.63% <BR>Price to Book: 4.86 <BR><BR>Contact Details: <BR>Address: Flat No. 2 RD Shah Building, Shraddanand Road Ghatkopar(W) Mumbai Maharashtra : 400086 <BR>Tel: 91-22-71975756/5656 <BR>Email: info@aspiradiagnostics.com/urkalsoa <BR>Website: http://www.aspiradiagnostics.com

Who are the top shareholders of the Aspira Pathlab?

The top shareholders of Aspira Pathlab are Deepali Arvind Bhanushali with 8.6% and Rinku Vinod Bhanushali with 8.1%. Individual investors own 60.46% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Aspira Pathlab include Deepali Arvind Bhanushali, who holds the highest promoter stake at 8.6%. Following her, the highest public shareholder is Rinku Vinod Bhanushali, with a holding of 8.1%. Additionally, individual investors collectively own a significant portion of the company, accounting for 60.46% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Aspira Pathlab?

As of 24th July, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 61.00 Cr, with recent net sales of 22.01 Cr and a net profit of 2.03 Cr. Shareholder's funds are 10.14 Cr and total assets amount to 14.71 Cr as of March 2024.

As of 24th July, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 61.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 22.01 Cr and a Net Profit of 2.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 10.14 Cr and Total Assets of 14.71 Cr.

How has been the historical performance of Aspira Pathlab?

Aspira Pathlab's financial performance improved significantly from March 2024 to March 2025, with net sales rising to 22.00 Cr from 13.20 Cr, and a turnaround from losses to a profit after tax of 2.02 Cr. Key metrics such as EPS and operating profit margin also showed positive growth, indicating a strengthened financial position.

Answer:<BR>Aspira Pathlab has shown significant improvement in its financial performance from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in the previous year. Total operating income also rose to 22.00 Cr from 13.20 Cr, while total expenditure increased to 18.83 Cr from 14.76 Cr. This led to an operating profit (PBDIT) of 3.56 Cr, a recovery from a loss of 1.14 Cr in the prior year. Profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, resulting in a profit after tax of 2.02 Cr compared to a loss of 2.67 Cr previously. The earnings per share (EPS) turned positive at 1.96, up from a negative 2.59. The operating profit margin also saw a significant turnaround, reaching 14.41% from -11.82%, while the profit after tax margin improved to 9.18% from -20.23%. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with total liabilities rising to 17.46 Cr from 14.71 Cr. The book value per share improved to 7.03 from 5.07, indicating a strengthening financial position. Cash flow from operating activities remained stable at 1.00 Cr, with a closing cash equivalent of 1.00 Cr, up from none in the previous year.

When is the next results date for Aspira Pathlab & Diagnostics Ltd?

The next results date for Aspira Pathlab & Diagnostics Ltd is 10 February 2026.

The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 10 February 2026.

Are Aspira Pathlab & Diagnostics Ltd latest results good or bad?

Aspira Pathlab & Diagnostics Ltd's latest results show strong year-on-year growth, with a 740% increase in net profit and a 13.15% rise in revenue. However, there are concerns due to a decline in both revenue and net profit compared to the previous quarter, indicating potential challenges in sustaining growth.

Aspira Pathlab & Diagnostics Ltd's latest results present a mixed picture. On one hand, the company has shown significant year-on-year growth, with a net profit of ₹0.42 crore in Q1 FY26, which is a remarkable increase of 740% compared to the same quarter last year. Revenue also rose by 13.15% year-on-year to ₹5.25 crore. Additionally, the operating margin improved to 13.9%, up 8.08 percentage points from the previous year.<BR><BR>However, the quarter-on-quarter performance raises concerns. Both revenue and net profit declined sequentially, with revenue down 9.17% and net profit down 38.24% from the previous quarter. This decline in performance suggests potential challenges in sustaining the recent growth momentum. <BR><BR>Overall, while the year-on-year improvements indicate a recovery from previous losses, the recent quarter's sequential declines point to volatility and uncertainty regarding the company's operational sustainability. Thus, the results can be seen as good in the context of year-on-year growth but concerning when considering the recent quarterly performance.

Should I buy, sell or hold Aspira Pathlab & Diagnostics Ltd?

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 17-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is currently Rs 54.28, reflecting a 3.69% decrease and significant underperformance compared to the Sensex. The stock has seen consecutive declines totaling 9.77% over two days and is trading below all major moving averages, indicating a bearish trend.

As of 17-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is falling, currently at Rs 54.28, which reflects a decrease of Rs 2.08 or 3.69%. The stock has been underperforming relative to the benchmark Sensex, with a performance today that is down by 4.24%. Over the past two days, the stock has experienced consecutive declines, totaling a drop of 9.77%. <BR><BR>Intraday trading has shown significant volatility, with the stock reaching a high of Rs 61.98 and a low of Rs 52.2, indicating a wide trading range of Rs 9.78. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a bearish trend. <BR><BR>Investor participation appears to be declining, as evidenced by a drop in delivery volume, which decreased by 0.98% compared to the 5-day average. Furthermore, the year-to-date performance shows a decline of 17.98%, compared to a lesser decline of 10.74% in the Sensex, indicating that the stock is not only falling but also lagging behind the broader market. Overall, these factors contribute to the current downward movement in the stock price of Aspira Pathlab & Diagnostics Ltd.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 18-Mar, Aspira Pathlab & Diagnostics Ltd is facing a significant decline in its stock price, currently at 54.00, with a total drop of -10.24% over the last three days and -38.64% over the past year. The company's poor financial performance, including an operating loss and a low EBIT to Interest ratio, further exacerbates its bearish momentum.

As of 18-Mar, Aspira Pathlab & Diagnostics Ltd is experiencing a decline in its stock price, currently at 54.00, which reflects a change of -0.28 (-0.52%). The stock has been underperforming significantly, with a consecutive fall over the last three days resulting in a total decline of -10.24%. This trend is compounded by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish momentum.<BR><BR>In the past week, the stock has decreased by -3.62%, while over the past month, it has fallen by -14.15%. Year-to-date, the stock has dropped -18.40%, and over the past year, it has seen a substantial decline of -38.64%, contrasting sharply with the Sensex, which has gained +1.86% during the same period. <BR><BR>The company's financial performance has also raised concerns, as it reported an operating loss with a poor EBIT to Interest ratio of 1.07, indicating a weak ability to service its debt. The latest quarterly results show a significant drop in profit after tax (PAT) of -510.5%, with net sales at their lowest of Rs 5.12 crore. Despite a rise in profits by 62% over the past year, the stock's overall performance remains negative, leading to a PEG ratio of 0.5, which suggests that the stock is undervalued compared to its earnings growth.<BR><BR>Additionally, the stock has underperformed the broader market, which has generated positive returns of 5.49% over the last year. This combination of poor financial indicators, consistent price declines, and underperformance relative to market benchmarks contributes to the ongoing fall in the stock price of Aspira Pathlab & Diagnostics Ltd.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 19-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is stagnant at 54.00, with significant declines over various time frames, including a 38.64% drop over the past year. The company faces operational losses and declining investor interest, overshadowing its attractive valuation metrics.

As of 19-Mar, Aspira Pathlab & Diagnostics Ltd is experiencing a stagnant stock price, currently at 54.00 with no change (0.00%). Despite outperforming its sector by 2.82% today, the stock has shown a significant decline over various time frames, including a 1-month decrease of 10.00% and a year-to-date drop of 18.40%. Over the past year, the stock has underperformed the market with a staggering decline of 38.64%, while the broader market (BSE500) has generated positive returns of 1.22%.<BR><BR>The company's financial health raises concerns, as it is facing operating losses and has a weak long-term fundamental strength, evidenced by a poor EBIT to Interest ratio of 1.07. Additionally, the latest quarterly results show a significant fall in profit after tax (PAT) by 510.5% to Rs -1.56 crore, alongside the lowest net sales of Rs 5.12 crore. The stock is also trading below its moving averages, indicating a bearish trend.<BR><BR>Investor participation has declined, with delivery volume falling by 44.81% against the 5-day average, suggesting reduced interest from investors. Although the company has an attractive valuation with a price-to-book value of 3.9 and a PEG ratio of 0.5, these factors are overshadowed by the company's operational challenges and negative performance metrics. Overall, the combination of poor financial results, declining investor interest, and underperformance relative to the market contributes to the stock's stagnant price and negative sentiment.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 20-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is rising to 55.10, reflecting a 2.04% increase due to strong intraday gains and increased investor interest. However, the company faces long-term challenges, including operating losses and weak debt servicing ability, despite a recent profit increase and trading at a discount to peers.

As of 20-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is rising, currently at 55.10, reflecting a change of 1.1 or 2.04% increase. This upward movement is primarily attributed to the stock opening with a significant gain of 10.93% today, reaching an intraday high of Rs 59.9. Additionally, the stock has outperformed its sector by 1.48%, indicating positive market sentiment.<BR><BR>Investor participation has also increased, with delivery volume rising by 100.54% against the 5-day average, suggesting heightened interest in the stock. However, despite this short-term rise, the company faces long-term challenges, including operating losses and a weak ability to service its debt, which may impact its future performance. <BR><BR>While the stock has generated a negative return of -40.27% over the past year, its profits have increased by 62%, and it is trading at a discount compared to its peers, which could be contributing factors to the current rise. Nonetheless, the overall long-term fundamental strength remains weak, as indicated by poor EBIT to interest ratios and significant declines in profit before tax and profit after tax in recent quarters.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 23-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is rising to 57.57, reflecting a 4.48% increase. This rise is driven by strong investor participation and outperformance against its sector, despite broader market declines.

As of 23-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is rising, currently at 57.57, reflecting a change of 2.47 (4.48%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 6.88% today and has shown a consecutive gain over the last two days, with a total return of 6.61% during this period. Additionally, the stock opened with a significant gain of 7.08% today and reached an intraday high of Rs 59.<BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume of 604 on 20 March, which is up by 3.99% compared to the 5-day average. Although the broader Hospital & Healthcare Services sector has declined by 2.37%, Aspira Pathlab's performance stands out positively against this backdrop. Furthermore, the stock's current price is higher than its 5-day moving averages, indicating a short-term upward trend, despite being lower than the longer-term moving averages. Overall, these factors contribute to the stock's rising price.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 24-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is Rs 54.10, down 3.55% after a trend reversal. The company faces significant financial challenges, including operating losses and a 46.80% decline in stock performance over the past year, leading to a strong sell recommendation.

As of 24-Mar, Aspira Pathlab & Diagnostics Ltd is experiencing a decline in its stock price, currently at Rs 54.10, reflecting a decrease of Rs 1.99 or 3.55%. This drop follows a trend reversal after three consecutive days of gains. Although the stock opened with a gain of 2.64% today, it reached an intraday high of Rs 57.57 before falling to a low of Rs 52.5, indicating significant volatility within the trading session.<BR><BR>The stock has underperformed its sector by 5.9% today and has shown a negative performance over various periods, including a year-to-date decline of 18.25% and a staggering 46.80% drop over the past year. This underperformance is stark compared to the broader market, where the Sensex has only declined by 5.02% over the same period.<BR><BR>Several factors contribute to this decline. The company is facing operating losses, with a poor EBIT to Interest ratio of 1.07, indicating weak financial health and an inability to service its debt effectively. Additionally, the recent quarterly results show a significant fall in profit after tax (PAT) by 510.5%, with net sales at their lowest of Rs 5.12 crore. Despite a rise in profits by 62% over the past year, the stock's return of -46.80% highlights a severe disconnect between profitability and stock performance.<BR><BR>Moreover, Aspira Pathlab is trading below its moving averages across multiple timeframes, suggesting a bearish trend. The stock's liquidity is adequate, but the overall sentiment remains negative, leading to a strong sell recommendation based on its weak long-term fundamental strength.

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 25-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is currently at Rs 58.00, showing a 7.21% increase today. While the stock has struggled over the past year with a -41.64% return, it is experiencing short-term positive sentiment due to recent gains and attractive valuation metrics despite underlying operational challenges.

As of 25-Mar, Aspira Pathlab & Diagnostics Ltd's stock price is rising, currently at Rs 58.00, reflecting a change of Rs 3.9 or 7.21% increase. This upward movement can be attributed to several factors. Firstly, the stock outperformed its sector by 4.94% today and opened with a significant gain of 6.4%. Additionally, it reached an intraday high of Rs 60.5, which is an increase of 11.83%.<BR><BR>Despite the positive performance today, it is important to note that the stock has faced challenges over the longer term. Over the past year, it has generated a return of -41.64%, which is significantly worse than the broader market's negative return of -0.34%. However, the company's profits have risen by 62%, and it is trading at a discount compared to its peers' average historical valuations, with a Price to Book Value of 4.1 and a PEG ratio of 0.6, indicating attractive valuation metrics.<BR><BR>The stock's recent rise may also be influenced by the overall positive movement in the Hospital & Healthcare Services sector, which gained 2.27%. However, it is essential to consider that the company is experiencing operational losses and has a weak long-term fundamental strength, as indicated by its poor EBIT to Interest ratio and declining quarterly profits. Despite these underlying issues, the stock's current rise reflects a short-term positive sentiment among investors.

Which are the latest news on Aspira Pathlab?